Compare Campbell Soup Co. (CPB) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Citius Pharmaceuticals Inc — how do they compare? Campbell Soup Co. trades at $22.79 (market cap $6.69B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Campbell Soup Co. is far larger — about 357.2× Citius Pharmaceuticals Inc's market cap, and Campbell Soup Co. pays a 6.96% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CPB | CTXR | |
|---|---|---|
Market Cap | $6.69B | $18.73M |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $1.82 |
52-Week Low | $20.00 | $0.48 |
Enterprise Value | $13.29B | $14.95M |
Dividend Yield | 6.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
